Literature DB >> 210263

Myasthenia gravis: further electrophysiological and ultrastructural analysis of transmission failure in the mouse passive transfer model.

K V Toyka, K L Birnberger, A P Anzil, C Schlegel, U Besinger, A Struppler.   

Abstract

Using the mouse passive transfer model the mean amplitude of miniature endplate potentials and endplate potentials of mice treated with myasthenic immunoglobulins was markedly decreased. Miniature endplate potential frequency and quantum content of endplate potentials were normal, arguing against a major presynaptic disarrangement. Under electron-microscopy no gross structural alterations of endplates were demonstrated. It is concluded that the mouse passive transfer model closely resembles human myasthenia gravis of recent onset.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 210263      PMCID: PMC1083392          DOI: 10.1136/jnnp.41.8.746

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  33 in total

1.  AN ELECTROPHYSIOLOGICAL INVESTIGATION OF NEUROMUSCULAR TRANSMISSION IN MYASTHENIA GRAVIS.

Authors:  D ELMQVIST; W W HOFMANN; J KUGELBERG; D M QUASTEL
Journal:  J Physiol       Date:  1964-11       Impact factor: 5.182

2.  The end-plate potential in mammalian muscle.

Authors:  I A BOYD; A R MARTIN
Journal:  J Physiol       Date:  1956-04-27       Impact factor: 5.182

3.  Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations.

Authors:  A G Engel; E H Lambert; F M Howard
Journal:  Mayo Clin Proc       Date:  1977-05       Impact factor: 7.616

4.  Myasthenia gravis serum reduces acetylcholine sensitivity in cultured rat myotubes.

Authors:  R Anwyl; S M Appel; T Narahashi
Journal:  Nature       Date:  1977-05-19       Impact factor: 49.962

5.  Intrathymic pathogenesis and dual genetic control of myasthenia gravis.

Authors:  H Wekerle; U P Ketelsen
Journal:  Lancet       Date:  1977-03-26       Impact factor: 79.321

6.  Human myasthenic sera reduce acetylcholine sensitivity of human muscle cells in tissue culture.

Authors:  S Bevan; R W Kullberg; S F Heinemann
Journal:  Nature       Date:  1977-05-19       Impact factor: 49.962

Review 7.  Immunology of the acetylcholine receptor.

Authors:  V A Lennon
Journal:  Immunol Commun       Date:  1976

8.  Accelerated degradation of acetylcholine receptor from cultured rat myotubes with myasthenia gravis sera and globulins.

Authors:  S H Appel; R Anwyl; M W McAdams; S Elias
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

9.  Myasthenic immunoglobulin accelerates acetylcholine receptor degradation.

Authors:  I Kao; D B Drachman
Journal:  Science       Date:  1977-04-29       Impact factor: 47.728

10.  Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model.

Authors:  A G Engel; J M Lindstrom; E H Lambert; V A Lennon
Journal:  Neurology       Date:  1977-04       Impact factor: 9.910

View more
  4 in total

1.  Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG.

Authors:  K V Toyka; B Löwenadler; K Heininger; U A Besinger; K L Birnberger; A Fateh-Moghadam; E Heilbronn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-09       Impact factor: 10.154

2.  Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor.

Authors:  C M Gomez; R L Wollmann; D P Richman
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

3.  [Demonstration of acetylcholine receptor antibodies in the serum of myasthenia gravis patients applying affinity chromatographically purified human acetylcholine receptor preparations (author's transl)].

Authors:  I Kalies; J R Kalden; F Heinz; R W Janzen; L Lachenmayer
Journal:  Klin Wochenschr       Date:  1979-09-03

Review 4.  Complement Inhibitor Therapy for Myasthenia Gravis.

Authors:  Khaled Albazli; Henry J Kaminski; James F Howard
Journal:  Front Immunol       Date:  2020-06-03       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.